Holen Sie sich die Stockscreener-App
20.27
3.38%
-0.7207
Schlusskurs vom Vortag:
$20.99
Offen:
$21.23
24-Stunden-Volumen:
576.86K
Relative Volume:
0.29
Marktkapitalisierung:
$2.24B
Einnahmen:
$6.94M
Nettoeinkommen (Verlust:
$-212.39M
KGV:
-8.3481
EPS:
-2.428
Netto-Cashflow:
$-200.60M
1W Leistung:
-3.61%
1M Leistung:
-8.48%
6M Leistung:
+120.20%
1J Leistung:
+127.10%
1-Tages-Spanne:
$19.81
$21.40
1-Wochen-Bereich:
$19.81
$22.16
52-Wochen-Spanne:
$5.1501
$27.65
Immunome Inc Stock (IMNM) Company Profile
Firmenname
Immunome Inc
Sektor
Branche
Telefon
610-321-3700
Adresse
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
20.31 | 2.32B | 6.94M | -212.39M | -200.60M | -2.428 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.85 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.44 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
703.52 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.31 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.77 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-12-01 | Eingeleitet | Truist | Buy |
| 2025-09-22 | Eingeleitet | Goldman | Buy |
| 2025-09-05 | Eingeleitet | Craig Hallum | Buy |
| 2025-04-02 | Eingeleitet | Lake Street | Buy |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-30 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-15 | Eingeleitet | Guggenheim | Buy |
| 2024-01-29 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-19 | Eingeleitet | Wedbush | Outperform |
| 2021-10-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Immunome Inc Aktie (IMNM) Neueste Nachrichten
Loss Report: Is Immunome Inc forming a breakout pattern2026 Risk Factors & Weekly Stock Breakout Alerts - baoquankhu1.vn
Bienaime buys Immunome (IMNM) shares worth $43,670 - Investing.com Nigeria
Insider Buying: Jean Bienaime Acquires Additional Shares of Immu - GuruFocus
Immunome (NASDAQ:IMNM) Director Acquires $21,550.00 in Stock - MarketBeat
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing - AOL.com
A Look At Immunome (IMNM) Valuation After Narrower 2025 Loss And New US$156 Million Shelf Registration - simplywall.st
Immunome: Upcoming NDA, Valuation, And Investment Case (NASDAQ:IMNM) - Seeking Alpha
(IMNM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Immunome (NASDAQ:IMNM) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Is Immunome Inc forming a breakout patternJuly 2025 Analyst Calls & Growth Focused Stock Pick Reports - baoquankhu1.vn
Did Reduced 2025 Losses and NDA Plans Just Shift Immunome's (IMNM) Investment Narrative? - Yahoo Finance
Whale Trades: How do insiders feel about Immunome IncMarket Sentiment Review & Entry and Exit Point Strategies - baoquankhu1.vn
HC Wainwright Brokers Raise Earnings Estimates for Immunome - MarketBeat
Immunome (IMNM) TTM Net Loss Of US$212 Million Reinforces Bearish Profitability Narratives - Sahm
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com
HC Wainwright Analysts Boost Earnings Estimates for Immunome - MarketBeat
IMNM: Stephens & Co. Lowers Price Target to $30, Maintains Overw - GuruFocus
Immunome (IMNM): Craig-Hallum Raises Price Target to $36.00 and - GuruFocus
Immunome (NASDAQ:IMNM) Price Target Raised to $36.00 - MarketBeat
Stephens Cuts Immunome (NASDAQ:IMNM) Price Target to $30.00 - MarketBeat
Decoding Immunome Inc (IMNM): A Strategic SWOT Insight - GuruFocus
Immunome (IMNM) Reports Wider Losses and Revenue Decline - GuruFocus
Immunome 2025 Net Loss Narrows - marketscreener.com
Immunome (IMNM) Projects Strong Cash Position and Promising Drug Developments - GuruFocus
Earnings Flash (IMNM) Immunome Posts Full Year 2025 Loss $2.43, vs. FactSet Est of $2.24 Loss - marketscreener.com
Immunome: Q4 Earnings Insights - Benzinga
IMNM: Net loss improved to $212.4M in 2025, with $653.5M cash supporting late-stage oncology pipeline - TradingView
Immunome (IMNM) 2025 10-K: Phase 3 varegacestat data and ADC pipeline - Stock Titan
Immunome (IMNM) posts 2025 loss but scores major Phase 3 cancer win - Stock Titan
Immunome Reports Full Year 2025 Financial Results and Provides Business Update - Business Wire
TD Asset Management Inc Purchases 95,750 Shares of Immunome, Inc. $IMNM - MarketBeat
How Immunome’s Oncology Pivot and Varegacestat NDA Push Could Impact Immunome (IMNM) Investors - simplywall.st
IMNM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development - Insider Monkey
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Immunome, Inc. (IMNM) Investor Outlook: Exploring a Promising 60% Upside in the Biotech Sector - DirectorsTalk Interviews
Private Capital Advisors Inc. Has $1.38 Million Stake in Immunome, Inc. $IMNM - MarketBeat
Assessing Immunome (IMNM) Valuation After Recent Share Price Pullback - Yahoo Finance
Immunome to Present at Upcoming March 2026 Investor Conferences - BioSpace
First Week of October 16th Options Trading For Immunome (IMNM) - Nasdaq
Immunome to Present at Upcoming Investor Conferences - The Joplin Globe
Biotech Immunome to face investors at two March conferences - Stock Titan
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% - Yahoo Finance
Risk Analysis: Is Immunome Inc part of any ETF2025 Year in Review & Technical Pattern Based Signals - baoquankhu1.vn
Immunome, Inc. $IMNM Shares Acquired by NEOS Investment Management LLC - MarketBeat
Immunome, Inc. (IMNM) - DirectorsTalk Interviews
Market Fear: Can Immunome Inc be the next market leaderShort Setup & Weekly Breakout Watchlists - baoquankhu1.vn
Is Immunome, Inc. (IMNM) the best booming stock to buy right now? - MSN
Jim Cramer on Immunome: "If you want to speculate on it, fine" - MSN
Should You Buy Immunome Inc (IMNM) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Redmile Group (IMNM) discloses 5.2% Immunome stake via managed funds - Stock Titan
Finanzdaten der Immunome Inc-Aktie (IMNM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunome Inc-Aktie (IMNM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
Mar 11 '26 |
Buy |
21.55 |
1,000 |
21,550 |
38,415 |
| SIEGALL CLAY B | President and CEO |
Dec 30 '25 |
Buy |
21.15 |
4,729 |
100,018 |
665,254 |
| Barchas Isaac | Director |
Dec 22 '25 |
Sale |
21.74 |
383,200 |
8,330,080 |
2,031,181 |
| SIEGALL CLAY B | President and CEO |
Dec 19 '25 |
Buy |
20.48 |
7,278 |
149,053 |
860,525 |
| Tsai Philip | Chief Technical Officer |
Dec 19 '25 |
Buy |
20.49 |
10,000 |
204,900 |
43,300 |
| SIEGALL CLAY B | President and CEO |
Dec 18 '25 |
Buy |
21.50 |
46,511 |
999,986 |
853,247 |
| Higgins Jack | Chief Scientific Officer |
Sep 10 '25 |
Option Exercise |
1.35 |
22,000 |
29,700 |
40,729 |
| BIENAIME JEAN JACQUES | Director |
Jun 03 '25 |
Buy |
9.38 |
5,000 |
46,900 |
36,415 |
| Higgins Jack | Chief Scientific Officer |
Mar 27 '25 |
Option Exercise |
1.35 |
5,200 |
7,020 |
18,729 |
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):